B Cells | CHOP Research Institute

B Cells

Published on
Mar 18, 2024
Learn how the NAD metabolite controls how well T and B cells can detect their antigens, leading to quicker immune responses.
Published on
Jan 24, 2022
Researchers identified aberrant splicing as a culprit behind treatment resistance in B-ALL.

Dr. Bailis aims to understand how metabolism underlies immunology and disease, by controlling the biochemistry of cells and tissues. His lab does so using in vitro and in vivo CRISPR engineering of primary human and mouse immune cells, with the goal of developing diet and metabolite based therapies.

bailisw [at] chop.edu

This is an open-label, four-cohort, phase 2 study to determine the efficacy of CART19.

This study will take the patients white blood cells - T cells - and change them to turn against the cancer.

This purpose of this study is to determine the efficacy of humanized CD19 CAR  T cells (huCART19) in pediatric and young adult patients with high-risk relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).

All biological processes operate under biochemical constraints. The Bailis Lab aims to understand how metabolism controls the development and functional differentiation of the hematopoietic system by setting the biochemical potential of cells and tissues, using in vitro and in vivo CRISPR screening in primary immune cells.